Jasper Therapeutics (NASDAQ:JSPR – Free Report) had its price objective decreased by Royal Bank of Canada from $68.00 to $48.00 in a research report sent to investors on Thursday morning,Benzinga reports.
Finally, BMO Capital Markets began coverage on Jasper Therapeutics in a research report on Friday, December 6th.
Get Jasper Therapeutics alerts:Read Our Latest Report on Jasper TherapeuticsJasper Therapeutics Stock PerformanceInstitutional Trading of Jasper TherapeuticsShares of NASDAQ:JSPR opened at $7.05 on Thursday.
Jasper Therapeutics Company Profile(Get Free Report)Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
See AlsoReceive News &amp; Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Royal Bank of Canada Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $48.00